NasdaqGS - Nasdaq Real Time Price USD

Zenas BioPharma, Inc. (ZBIO)

28.39 -0.37 (-1.29%)

At close: October 30 at 4:00:00 PM EDT

28.39 0.00 (0.00%)

After hours: October 30 at 4:00:16 PM EDT

Trade ZBIO on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for ZBIO

Previous Close 28.76
Open 28.35
Bid 20.24 x 200
Ask 36.32 x 200
Day's Range 27.91 - 29.11
52 Week Range 13.50 - 44.60
Volume 358,070
Avg. Volume 647,937
Market Cap (intraday) 1.85B
Beta (5Y Monthly) -0.88
PE Ratio (TTM) --
EPS (TTM) -9.63
Earnings Date (est.) Nov 12, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 47.88
Zacks Rating Bullish

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

zenasbio.com

167

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ZBIO

21.81%

S&P 500 (^GSPC)

10.73%

1-Year Return

ZBIO

4.99%

S&P 500 (^GSPC)

11.11%

3-Year Return

ZBIO

54.71%

S&P 500 (^GSPC)

81.91%

5-Year Return

ZBIO

54.71%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue 1M

Earnings -111.46M

Profit Margin -11,145.60%

FY25

FY26

-200M

-150M

-100M

-50M

-10000.0%

-8000.0%

-6000.0%

-4000.0%

-2000.0%

0.0%

Analyst Price Targets

32.00

47.88 Average

28.39 Current

59.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 10/13/2026

Analyst HC Wainwright & Co.

Rating Action Reiterates

Rating Buy

Price Action Maintains

Price Target 44 -> 44

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-34.42%
Return on Equity (ttm)

-199.04%
Revenue (ttm)

1M
Net Income Avi to Common (ttm)

-484.38M
Diluted EPS (ttm)

-9.63

Balance Sheet and Cash Flow

Total Cash (mrq)

643.13M
Total Debt/Equity (mrq)

120.54%
Levered Free Cash Flow (ttm)

-211.39M

MBX

BCAX

UPB

ALMS

RAPP

U.S. markets closed

Zenas BioPharma, Inc. (ZBIO)

Trading disclosure

5.66%

5.27%

46.95%

-21.81%

-4.99%

54.71%

54.71%

Zenas BioPharma, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch